Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2013

01-02-2013

Alterations of fibrin network structure mediated by dermatan sulfate

Authors: Ana María Lauricella, María Mercedes Castañon, Lucía C. Kordich, Irene L. Quintana

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2013

Login to get access

Abstract

Dermatan sulfate (DS) is well-known for its anticoagulant activity through binding to heparin cofactor II (HCII) to enhance thrombin inhibition. It has also been reported that DS has a profibrinolytic effect. We have evaluated the effects of DS solutions (4–20 μg/mL) on the formation (by kinetic studies), structure (by electron microscopy and compaction assays) and lysis (with urokinase-type plasminogen activator) of plasma fibrin networks. The results showed that DS significantly prolonged the lag phase and decreased the fibrin formation rate and the optical density of the final networks versus control, in a concentration dependent way. DS-associated networks presented a minor network percentage compared with control, composed of lower number of fibers per field, which resulted significantly thinner and longer. Moreover, DS rendered gels more sensible to rupture by centrifugal force and more susceptible to lysis. When fibrin formation kinetic assays were performed with purified fibrinogen instead of plasma, in the absence of HCII, the optical density of final DS-associated networks was statistically lower than control. Therefore, a direct effect of DS on the thickness of fibers was observed. Since in all in vitro assays low DS concentrations were used, it could be postulated that the fibrin features described above are plausible to be found in in vivo thrombi and therefore, DS would contribute to the formation of less thrombogenic clots.
Literature
1.
go back to reference Casu B (1991) Structural features and binding properties of chondroitin sulfate, dermatan sulfate and heparan sulfate. Semin Thromb Hemost 17:9–14PubMed Casu B (1991) Structural features and binding properties of chondroitin sulfate, dermatan sulfate and heparan sulfate. Semin Thromb Hemost 17:9–14PubMed
2.
go back to reference Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B (1992) An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 89:321–326PubMedCrossRef Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B (1992) An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 89:321–326PubMedCrossRef
3.
go back to reference Delorme MA, Saees N, Sevick A, Mitchell L, Berry L, Johnston M, Andrew M (1993) Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis. Blood 82:3380–3385PubMed Delorme MA, Saees N, Sevick A, Mitchell L, Berry L, Johnston M, Andrew M (1993) Plasma dermatan sulfate proteoglycan in a patient on chronic hemodialysis. Blood 82:3380–3385PubMed
4.
go back to reference Rossi E, Duboscq C, Peragallo M, Kordich L (1997) Heparin cofactor II (HC II) and dermatan sulfate plasmatic levels in acute burnt patients. Thromb Haemost Suppl:435 Rossi E, Duboscq C, Peragallo M, Kordich L (1997) Heparin cofactor II (HC II) and dermatan sulfate plasmatic levels in acute burnt patients. Thromb Haemost Suppl:435
5.
go back to reference Saito A, Munakata H (2007) Analysis of plasma proteins that binds to glycosaminoglycans. Biochim Biophys Acta 1770:241–246PubMedCrossRef Saito A, Munakata H (2007) Analysis of plasma proteins that binds to glycosaminoglycans. Biochim Biophys Acta 1770:241–246PubMedCrossRef
6.
go back to reference Rau J, Mitchell J, Fortenberry Y, Church F (2011) Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost 37:339–348PubMedCrossRef Rau J, Mitchell J, Fortenberry Y, Church F (2011) Heparin cofactor II: discovery, properties, and role in controlling vascular homeostasis. Semin Thromb Hemost 37:339–348PubMedCrossRef
7.
go back to reference Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourão PA (2005) Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 1740:45–53PubMedCrossRef Tovar AM, de Mattos DA, Stelling MP, Sarcinelli-Luz BS, Nazareth RA, Mourão PA (2005) Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 1740:45–53PubMedCrossRef
8.
go back to reference Han JH, Cote HCF, Tollefsen DM (1997) Inhibition of meizothrombin and meizothrombin(des F1) by heparin cofactor II. J Biol Chem 272:28660–28665PubMedCrossRef Han JH, Cote HCF, Tollefsen DM (1997) Inhibition of meizothrombin and meizothrombin(des F1) by heparin cofactor II. J Biol Chem 272:28660–28665PubMedCrossRef
9.
go back to reference Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI (2001) Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276:20959–22065PubMedCrossRef Liaw PC, Becker DL, Stafford AR, Fredenburgh JC, Weitz JI (2001) Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 276:20959–22065PubMedCrossRef
10.
go back to reference Iacoviello L, D’Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB (1996) Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 76:1102–1107PubMed Iacoviello L, D’Adamo MC, Pawlak K, Polishchuck R, Wollny T, Buczko W, Donati MB (1996) Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis. Thromb Haemost 76:1102–1107PubMed
11.
go back to reference Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B (1992) Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 68:637–641PubMed Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B (1992) Effects of heparin, dermatan sulphate and of their association on the inhibition of venous thrombosis growth in the rabbit. Thromb Haemost 68:637–641PubMed
12.
go back to reference Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. Pharmacoeconomics 19:57–68PubMedCrossRef Attanasio E, Russo P, Carunchio G, Caprino L (2001) Dermatan sulfate versus unfractionated heparin for the prevention of venous thromboembolism in patients undergoing surgery for cancer. A cost-effectiveness analysis. Pharmacoeconomics 19:57–68PubMedCrossRef
13.
go back to reference Imberti D, Verso M, Silvestrini E, Taliani MR, Agnelli G (2003) Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost 1:2696–2697PubMedCrossRef Imberti D, Verso M, Silvestrini E, Taliani MR, Agnelli G (2003) Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism. J Thromb Haemost 1:2696–2697PubMedCrossRef
14.
go back to reference Castañon MM, Gamba C, Kordich LC (2007) Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators. Thromb Res 120:745–752PubMedCrossRef Castañon MM, Gamba C, Kordich LC (2007) Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators. Thromb Res 120:745–752PubMedCrossRef
15.
go back to reference Stirling Y, Woolf L, North W, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52:176–182PubMed Stirling Y, Woolf L, North W, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52:176–182PubMed
16.
go back to reference Wickström K, Edelstam G, Löwbeer C, Hansson L, Siebahn A (2004) Reference intervals for plasma levels of fibrinectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31–40PubMedCrossRef Wickström K, Edelstam G, Löwbeer C, Hansson L, Siebahn A (2004) Reference intervals for plasma levels of fibrinectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 64:31–40PubMedCrossRef
17.
go back to reference Delorme M, Burrows R, Ofosu F, Andrew M (1992) Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost 18:81–90PubMedCrossRef Delorme M, Burrows R, Ofosu F, Andrew M (1992) Thrombin regulation in mother and fetus during pregnancy. Semin Thromb Hemost 18:81–90PubMedCrossRef
18.
go back to reference Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U (1996) Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 82:109–117PubMedCrossRef Andersson T, Lorentzen B, Hogdahl H, Clausen T, Mowinckel MC, Abildgaard U (1996) Thrombin-inhibitor complexes in the blood during and after delivery. Thromb Res 82:109–117PubMedCrossRef
19.
go back to reference Giri TK, Tollefsen DM (2006) Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 107:2753–2758PubMedCrossRef Giri TK, Tollefsen DM (2006) Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II. Blood 107:2753–2758PubMedCrossRef
20.
go back to reference Weisel JW, Litvinov RI (2008) The biochemical and physical process of fibrinolysis and effects of clots structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6:161–180PubMedCrossRef Weisel JW, Litvinov RI (2008) The biochemical and physical process of fibrinolysis and effects of clots structure and stability on the lysis rate. Cardiovasc Hematol Agents Med Chem 6:161–180PubMedCrossRef
21.
go back to reference Lauricella AM, Quintana I, Castañon M, Sassetti B, Kordich L (2006) Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 17:181–186PubMedCrossRef Lauricella AM, Quintana I, Castañon M, Sassetti B, Kordich L (2006) Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 17:181–186PubMedCrossRef
22.
go back to reference Nair CH, Shats EA (1997) Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to crosslinking. Thromb Res 88:381–387PubMedCrossRef Nair CH, Shats EA (1997) Compaction as a method to characterize fibrin network structure: kinetic studies and relationship to crosslinking. Thromb Res 88:381–387PubMedCrossRef
23.
go back to reference Colliec S, Fischer AM, Tapon-Bretaudiere J, Boisson C, Durand P, Jozefonvicz J (1991) Anticoagulant properties of a fucoidan fraction. Thromb Res 64:143–154PubMedCrossRef Colliec S, Fischer AM, Tapon-Bretaudiere J, Boisson C, Durand P, Jozefonvicz J (1991) Anticoagulant properties of a fucoidan fraction. Thromb Res 64:143–154PubMedCrossRef
24.
go back to reference Weisel JW, Veklich Y, Collet JP, Francis CW (1999) Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 82:277–282PubMed Weisel JW, Veklich Y, Collet JP, Francis CW (1999) Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 82:277–282PubMed
25.
go back to reference Wolberg AS, Gabriel DA, Hoffman M (2002) Analysing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 13:533–539PubMedCrossRef Wolberg AS, Gabriel DA, Hoffman M (2002) Analysing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 13:533–539PubMedCrossRef
26.
go back to reference Jones M, Gabriel DA (1988) Influence of subendothelial basement membrane components on fibrin assembly. J Biol Chem 263:7043–7048PubMed Jones M, Gabriel DA (1988) Influence of subendothelial basement membrane components on fibrin assembly. J Biol Chem 263:7043–7048PubMed
27.
go back to reference Litvinov RI, Yakovlev S, Tsurupa G, Gorkun OV, Medved L, Weisel JW (2007) Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 46:9133–9142PubMedCrossRef Litvinov RI, Yakovlev S, Tsurupa G, Gorkun OV, Medved L, Weisel JW (2007) Direct evidence for specific interactions of the fibrinogen alphaC-domains with the central E region and with each other. Biochemistry 46:9133–9142PubMedCrossRef
28.
go back to reference Weisel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5(Suppl. 1):116–124PubMedCrossRef Weisel J (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5(Suppl. 1):116–124PubMedCrossRef
29.
go back to reference Undas A, Ariëns R (2011) Fibrin clot structure and function. A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:88–99CrossRef Undas A, Ariëns R (2011) Fibrin clot structure and function. A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 31:88–99CrossRef
Metadata
Title
Alterations of fibrin network structure mediated by dermatan sulfate
Authors
Ana María Lauricella
María Mercedes Castañon
Lucía C. Kordich
Irene L. Quintana
Publication date
01-02-2013
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2013
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-012-0804-9

Other articles of this Issue 2/2013

Journal of Thrombosis and Thrombolysis 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.